...
首页> 外文期刊>Molecules >Improved Oral Bioavailability Using a Solid Self-Microemulsifying Drug Delivery System Containing a Multicomponent Mixture Extracted from Salvia miltiorrhiza
【24h】

Improved Oral Bioavailability Using a Solid Self-Microemulsifying Drug Delivery System Containing a Multicomponent Mixture Extracted from Salvia miltiorrhiza

机译:使用包含自丹参提取物的多组分混合物的固体自微乳化药物递送系统改善口服生物利用度

获取原文
获取原文并翻译 | 示例

摘要

The active ingredients of salvia (dried root of Salvia miltiorrhiza) include both lipophilic (e.g., tanshinone IIA, tanshinone I, cryptotanshinone and dihydrotanshinone I) and hydrophilic (e.g., danshensu and salvianolic acid B) constituents. The low oral bioavailability of these constituents may limit their efficacy. A solid self-microemulsifying drug delivery system (S-SMEDDS) was developed to load the various active constituents of salvia into a single drug delivery system and improve their oral bioavailability. A prototype SMEDDS was designed using solubility studies and phase diagram construction, and characterized by self-emulsification performance, stability, morphology, droplet size, polydispersity index and zeta potential. Furthermore, the S-SMEDDS was prepared by dispersing liquid SMEDDS containing liposoluble extract into a solution containing aqueous extract and hydrophilic polymer, and then freeze-drying. In vitro release of tanshinone IIA, salvianolic acid B, cryptotanshinone and danshensu from the S-SMEDDS was examined, showing approximately 60%-80% of each active component was released from the S-SMEDDS in vitro within 20 min. In vivo bioavailability of these four constituents indicated that the S-SMEDDS showed superior in vivo oral absorption to a drug suspension after oral administration in rats. It can be concluded that the novel S-SMEDDS developed in this study increased the dissolution rate and improved the oral bioavailability of both lipophilic and hydrophilic constituents of salvia. Thus, the S-SMEDDS can be regarded as a promising new method by which to deliver salvia extract, and potentially other multicomponent drugs, by the oral route.
机译:丹参的活性成分(丹参的干燥根)包括亲脂性(例如丹参酮IIA,丹参酮I,隐丹参酮和二氢丹参酮I)和亲水性(例如丹参素和丹酚酸B)成分。这些成分的口服生物利用度低可能会限制其功效。开发了一种固体自微乳化药物输送系统(S-SMEDDS),可将丹参的各种活性成分加载到单个药物输送系统中,并提高其口服生物利用度。利用溶解度研究和相图设计方法设计了SMEDDS原型,并具有自乳化性能,稳定性,形态,液滴尺寸,多分散指数和Zeta电位的特征。此外,通过将包含脂溶性提取物的液体SMEDDS分散到包含水提取物和亲水性聚合物的溶液中,然后冷冻干燥来制备S-SMEDDS。检查了丹参酮IIA,丹酚酸B,隐丹参酮和丹参素从S-SMEDDS的体外释放,显示大约20%-80%的每种活性成分均在20分钟内从S-SMEDDS释放。这四种成分的体内生物利用度表明,S-SMEDDS在大鼠口服后显示出优于药物悬液的体内口服吸收。可以得出结论,这项研究中开发的新型S-SMEDDS提高了丹参的亲脂性和亲水性成分的溶出率并提高了其口服生物利用度。因此,S-SMEDDS可以被认为是一种有前途的新方法,通过它可以通过口服途径输送丹参提取物和潜在的其他多组分药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号